Literature DB >> 28212997

Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.

Young Wha Koh1, Su Jin Lee2, Seong Yong Park3.   

Abstract

BACKGROUND: We evaluated glucose transporter type 1 (GLUT1) and carbonic anhydrase IX (CAIX) expression, together with volume-based18F-fluorodeoxyglucose positron emission tomography (FDG-PET) parameters, in non-small cell lung cancer (NSCLC) patients, and examined the prognostic significance of those parameters according to its histologic subtype.
METHOD: A total of 269 patients, who underwent surgical resection for NSCLC, were reviewed retrospectively. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) values were measured by preoperative 18F-fluorodeoxyglucose positron emission tomography computed tomography. GLUT1 and CAIX expression was evaluated using immunohistochemical method.
RESULTS: The mean MTV and TLG values were 30.0±57.1 and 165.4±361.3, respectively, and were significantly higher in patients with squamous cell carcinoma than with adenocarcinoma (p=0.047 for MTV; p=0.042 for TLG). GLUT1 expression was identified in 99% of squamous cell carcinoma and 50% of adenocarcinoma patients. MTV and TLG values were significantly higher in GLUT1-positive than GLUT-negative adenocarcinomas; however, CAIX expression did not show this pattern. GLUT1-positive adenocarcinoma patients had a lower OS than GLUT1-negative patients (p<0.001), whereas CAIX-positive and CAIX-negative patients showed similar OS rates (p=0.226). Patients with high MTV and TLG values showed lower OS rates than those with low MTV and TLG values. Multivariate analysis showed that GLUT1 positivity was an independent risk factor for a lower OS rate in lung adenocarcinoma patients (hazard ratio=2.574, p=0.016). GLUT1 expression was associated with micropapillary/solid histology, lymphovascular invasion, and advanced pTNM stage.
CONCLUSIONS: MTV and TLG values, and GLUT1 expression, significantly differed between patients with squamous cell carcinoma and adenocarcinoma. High GLUT1 expression levels were significantly associated with MTV and TLG values and adverse clinical outcomes in patients with adenocarcinoma. Copyright Â
© 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  CAIX; GLUT1; Metabolic tumor volume; Non-small cell lung cancer; Total lesion glycolysis

Mesh:

Substances:

Year:  2016        PMID: 28212997     DOI: 10.1016/j.lungcan.2016.12.003

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  24 in total

1.  GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome.

Authors:  Salma Meziou; Cassandra Ringuette Goulet; Hélène Hovington; Véronique Lefebvre; Étienne Lavallée; Michelle Bergeron; Hervé Brisson; Audrey Champagne; Bertrand Neveu; Didier Lacombe; Jean-Mathieu Beauregard; François-Alexandre Buteau; Julie Riopel; Frédéric Pouliot
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-01-13       Impact factor: 5.554

Review 2.  Drugging cancer metabolism: Expectations vs. reality.

Authors:  David C Montrose; Lorenzo Galluzzi
Journal:  Int Rev Cell Mol Biol       Date:  2019-07-29       Impact factor: 6.813

3.  Papillary Renal Cell Carcinomas Demonstrating Micropapillary Features: An Investigation Into the Diagnostic and Prognostic Implications.

Authors:  Beatriz Caraballo; Maha Abdulla; Sunder Sham; Guang-Qian Xiao; Pamela Unger
Journal:  Cureus       Date:  2022-05-12

4.  The lncRNA PVT1 promotes invasive growth of lung adenocarcinoma cells by targeting miR-378c to regulate SLC2A1 expression.

Authors:  Hongwei Xia; Zhiqiang Zhang; Jun Yuan; Qingling Niu
Journal:  Hum Cell       Date:  2020-09-22       Impact factor: 4.174

5.  A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells.

Authors:  Yan Liang; Jing Zhang; Baocheng Tian; Zimei Wu; Darren Svirskis; Jingtian Han
Journal:  Int J Nanomedicine       Date:  2020-02-05

6.  Predictive Value of Preoperative Volume-Based 18F-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography/Computed Tomography Parameters in Patients with Resectable Lung Adenocarcinoma.

Authors:  Sunju Choi; Hye Ryeong Kwon; Hee Young Cho; Kisoo Pahk; Sung-Ho Lee; Jae-Ho Chung; Hyun Woo Kwon; Sungeun Kim
Journal:  Nucl Med Mol Imaging       Date:  2018-11-07

Review 7.  Metabolic Classification and Intervention Opportunities for Tumor Energy Dysfunction.

Authors:  Ezequiel Monferrer; Isaac Vieco-Martí; Amparo López-Carrasco; Fernando Fariñas; Sergio Abanades; Luis de la Cruz-Merino; Rosa Noguera; Tomás Álvaro Naranjo
Journal:  Metabolites       Date:  2021-04-23

8.  Glucose Transporter-1 Cooperating with AKT Signaling Promote Gastric Cancer Progression.

Authors:  Diyuan Zhou; Linhua Jiang; Lichen Jin; Yizhou Yao; Peijie Wang; Xinguo Zhu
Journal:  Cancer Manag Res       Date:  2020-06-03       Impact factor: 3.989

9.  Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: a pooled analysis of 1665 patients.

Authors:  Zhibo Tan; Chao Yang; Xiaohan Zhang; Pingju Zheng; Weixi Shen
Journal:  Oncotarget       Date:  2017-05-04

Review 10.  Heterogeneity of Glucose Transport in Lung Cancer.

Authors:  Cesar A Martinez; Claudio Scafoglio
Journal:  Biomolecules       Date:  2020-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.